Stunning Myeloma Marker Results

In the three weeks of this new three-drug regimen, Pomalyst, Darzalex, and dexamethasone (DEX), IgG has dropped 39%, from 1330 mg/dL to 807 mg/dL, in tests done by Mayo Clinic.  This spectacular result brings IgG to the lowest level I have seen since my diagnosis in 2003.  To confirm that result M-Spike dropped 33%, from 1.2 to 0.8 g/dL, also the lowest value since 2003, when it was measured once at 0.52 g/dL. This appears to be a spectacularly good omen, but a few things temper my enthusiasm just a little: 1. Three weeks ago, at the beginning of the new regimen, my blood also contained about a half dose of a different monoclonal antibody, unnamed because it was part of a study.  That agent declines in strength with about a four week half life, and it had been about four weeks.  Thus I have actually been treated by a four-drug combination, with one drug half gone and gradually disappearing.  We don't know what will happen when it is entirely gone.  No one has done this before. 2. Just yesterday, after the blood was taken for these tests, we reduced the DEX and moved the day that I take it to the night before the infusion.  The goal is to reduce the side effects of the DEX, but going forward it might also reduce its benefit if we're unlucky with this change. 3. In any case, three weeks is just not enough time to evaluate a new regimen.  Stuff happens. Despite all of this temperance talk, todays results are amazing and wonderful. &nb...
Source: Myeloma Hope - Category: Cancer & Oncology Tags: Darzalex dexamethasone Pomalyst Source Type: blogs

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
nni Monteleone Cross-talk between cancer cells and the immune cells occurring in the tumor microenvironment is crucial in promoting signals that foster tumor growth and metastasis. Both cancer cells and immune cells secrete various interleukins (IL), which, either directly or indirectly, stimulate cancer-cell proliferation, survival, and diffusion, as well as contribute to sculpt the immune microenvironment, thereby amplifying tumorigenic stimuli. IL-34, a cytokine produced by a wide range of cells, has been initially involved in the control of differentiation, proliferation, and survival of myeloid cells. More recent ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 17 January 2020Source: Best Practice &Research Clinical HaematologyAuthor(s): Dickran Kazandjian, Alexander Dew, Elizabeth HillAbstractState of the art treatment for myeloma involves using 3-drug combinations incorporating immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Clinical trials for 4-drug combinations incorporating monoclonal antibodies added to IMiD and PI based backbones are underway. Recent retrospective analyses show that patients who attain MRD negativity have similar long term outcomes regardless of early or delayed high dose melphalan with autologous ste...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with ris...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
Publication date: Available online 17 January 2020Source: Best Practice &Research Clinical HaematologyAuthor(s): Gary A. Ulaner, C. Ola LandgrenAbstractFluorine-18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) allows evaluation of elevated glucose metabolism in malignancies. There has been increasing interest in FDG PET/CT for plasma cell disorders since the International Myeloma Working Group outlined multiple applications of this imaging modality, including distinguishing smoldering myeloma from active multiple myeloma, confirmation of solitary plasmacytoma, and multiple indications in patients wi...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 17 January 2020Source: Best Practice &Research Clinical HaematologyAuthor(s): Even H. Rustad, Eileen M. BoyleAbstractAchieving minimal residual disease (MRD) negativity in the bone marrow is one of the strongest prognostic factors in multiple myeloma. Consequently, MRD testing is routinely performed in clinical trials and moving towards standard of care. This review focuses on the role of next generation sequencing (NGS) of tumor-specific immunoglobulin V(D)J sequences for MRD tracking. The immunoglobulin variable regions are ideal targets for tracking, because every tumor cell shares...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 16 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Bei Xiong, Mei Xue, Yalan Yu, Sanyun Wu, Xuelan ZuoAbstractTo investigate the clinical implications of SF3B1 mutation and ring sideroblasts in myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD), 238 consecutive MDS-RCMD patients were included in this study. Our results showed that SF3B1 mutation in MDS- RCMD patients identifies a distinct subgroup characterized by a high prevalence of erythroid dysplasia and a high proportion of ring sideroblasts, prolonged survival and reduced leukem...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe present analysis identifies disparities in the initial management of older adults with FL owing to race and socioeconomic status. Future research should examine implications for subsequent treatment and health outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionLncRNA MALAT1 expedited MM tumorigenesis, invasion, and glycolysis via miR-1271-5p/SOX13 axis. MALAT1 might contribute to the therapy of MM as a promising indicator.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Dexamethasone | Myeloma | Study